Skip to content
2000
image of Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer

Abstract

Introduction

Oxaliplatin is a third-generation platinum-based chemotherapeutic agent widely used for colorectal cancer treatment. However, its therapeutic application is limited by low solubility, systemic toxicity, and poor bioavailability.

Methods

Solid lipid nanoparticles (SLNs) were prepared using a micro-emulsion technique and further optimized via Box-Behnken Design (BBD), considering key formulation variables including Glyceryl Monostearate, Soya Lecithin, and Tween 80. Nanoparticles were characterized by drug release, drug loading, encapsulation efficiency, zeta potential, particle size, and polydispersity index (PDI). Cytotoxic efficacy against the HT-29 colorectal cancer cell line was evaluated using the Sulforhodamine B (SRB) assay.

Results

The optimized SLN formulation exhibited a mean particle size of 115.41 nm, PDI of 0.202, and zeta potential of +23.1 mV, indicating stability and efficient cellular uptake. Drug loading and encapsulation efficiency were 10.2±0.4% and 92±3.2%, respectively. In vitro release studies showed sustained drug release, reaching 97% over 48 hours. Cytotoxicity assays demonstrated enhanced efficacy of Oxaliplatin SLNs, with IC values of 0.9751 µg/mL at 24h and 1.168 µg/mL at 48h, compared to free Oxaliplatin (52.95 µg/mL at 24h and 16.33 µg/mL at 48h).

Discussion

GMS-based SLNs optimized with Tween 80, lecithin, and DDAB exhibited ideal size, charge, and high encapsulation. FTIR and DSC analyses confirmed component compatibility. The formulation showed sustained release and enhanced cytotoxicity, highlighting its potential to improve Oxaliplatin delivery and therapeutic efficacy in colorectal cancer.

Conclusion

The optimized Oxaliplatin SLNs demonstrated improved solubility, controlled release, and enhanced cytotoxicity, confirming their promise as a nanocarrier system for colorectal cancer therapy. Further in vivo studies are required to validate clinical effectiveness.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096414252251125053406
2026-01-12
2026-02-25

  • From This Site

    /content/journals/ccdt/10.2174/0115680096414252251125053406
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Comella P. Casaretti R. Sandomenico C. Avallone A. Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Ther. Clin. Risk Manag. 2009 5 1 229 238 10.2147/TCRM.S3583 19436599
    [Google Scholar]
  2. Díaz-Rubio E. Sastre J. Zaniboni A. Labianca R. Cortés-Funes H. de Braud F. Boni C. Benavides M. Dallavalle G. Homerin M. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Ann. Oncol. 1998 9 1 105 108 10.1023/A:1008200825886 9541691
    [Google Scholar]
  3. Alcindor T. Beauger N. Oxaliplatin: A review in the era of molecularly targeted therapy. Curr. Oncol. 2011 18 1 18 25 10.3747/co.v18i1.708 21331278
    [Google Scholar]
  4. Saif M.W. Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther. Clin. Risk Manag. 2005 1 4 249 258 [PMID: 18360567
    [Google Scholar]
  5. Hatakeyama S. Suzuki N. Abe K. Konno N. Kaneko T. Toyoguchi T. Shiraishi T. Effects of serum sodium concentrations on nausea and vomiting after moderately emetogenic chemotherapy. Yakugaku Zasshi 2018 138 8 1095 1101 10.1248/yakushi.18‑00009 30068850
    [Google Scholar]
  6. Wang Z. Wu M. Gou S. Toward a better understanding of the oxaliplatin mode of action upon the steric hindrance of 1,2-diaminocyclohexane and its analogue. J. Inorg. Biochem. 2016 157 1 7 10.1016/j.jinorgbio.2016.01.011 26816108
    [Google Scholar]
  7. Branca J.J.V. Carrino D. Gulisano M. Ghelardini C. Di Cesare Mannelli L. Pacini A. Oxaliplatin-induced neuropathy: Genetic and epigenetic profile to better understand how to ameliorate this side effect. Front. Mol. Biosci. 2021 8 643824 10.3389/fmolb.2021.643824 34026827
    [Google Scholar]
  8. Mohammadi-Samani S. Ghasemiyeh P. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res. Pharm. Sci. 2018 13 4 288 303 10.4103/1735‑5362.235156 30065762
    [Google Scholar]
  9. Nguyen T-T-L. Duong V-A. Solid Lipid Nanoparticles Encyclopedia 2022 2 2 952 973
    [Google Scholar]
  10. Correia A.C. Moreira J.N. Lobo Sousa J.M.; Silva, A.C. Design of experiment (DoE) as a quality by design (QbD) tool to optimise formulations of lipid nanoparticles for nose-to-brain drug delivery. Expert Opin. Drug Deliv. 2023 20 12 1731 1748 10.1080/17425247.2023.2274902 37905547
    [Google Scholar]
  11. Gupta S. Kesarla R. Chotai N. Misra A. Omri A. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. BioMed Res. Int. 2017 2017 1 18 10.1155/2017/5984014 28243600
    [Google Scholar]
  12. Rahmanian-Devin P. Askari V.R. Sanei-Far Z. Baradaran Rahimi V. Kamali H. Jaafari M.R. Golmohammadzadeh S. Preparation and characterization of solid lipid nanoparticles encapsulated noscapine and evaluation of its protective effects against imiquimod-induced psoriasis-like skin lesions. Biomed. Pharmacother. 2023 168 115823 10.1016/j.biopha.2023.115823 37924792
    [Google Scholar]
  13. Chen Y. Liang J. Chen S. Lin N. Xu S. Miao J. Zhang J. Chen C. Yuan X. Xie Z. Zhu E. Cai M. Wei X. Hou S. Tang H. Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer. Mol. Cancer 2024 23 1 196 10.1186/s12943‑024‑02108‑6 39272040
    [Google Scholar]
  14. Onugwu A.L. Attama A.A. Nnamani P.O. Onugwu S.O. Onuigbo E.B. Khutoryanskiy V.V. Development and optimization of solid lipid nanoparticles coated with chitosan and poly(2-ethyl-2-oxazoline) for ocular drug delivery of ciprofloxacin. J. Drug Deliv. Sci. Technol. 2022 74 103527 10.1016/j.jddst.2022.103527
    [Google Scholar]
  15. Harish V. Tewari D. Mohd S. Govindaiah P. Babu M.R. Kumar R. Gulati M. Gowthamarajan K. Madhunapantula S.V. Chellappan D.K. Gupta G. Dua K. Dallavalasa S. Singh S.K. Quality by design based formulation of xanthohumol loaded solid lipid nanoparticles with improved bioavailability and anticancer effect against pc-3 cells. Pharmaceutics 2022 14 11 2403 10.3390/pharmaceutics14112403 36365221
    [Google Scholar]
  16. Cavendish M. Nalone L. Barbosa T. Barbosa R. Costa S. Nunes R. da Silva C.F. Chaud M.V. Souto E.B. Hollanda L. Severino P. Study of pre-formulation and development of solid lipid nanoparticles containing perillyl alcohol. J. Therm. Anal. Calorim. 2020 141 2 767 774 10.1007/s10973‑019‑09080‑0
    [Google Scholar]
  17. Cheraga N. Ouahab A. Shen Y. Huang N.P. Characterization and pharmacokinetic evaluation of oxaliplatin long‐circulating liposomes. BioMed Res. Int. 2021 2021 1 5949804 10.1155/2021/5949804 33987441
    [Google Scholar]
  18. Rahman Z. Zidan A.S. Khan M.A. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 2010 76 1 127 137 10.1016/j.ejpb.2010.05.003 20470882
    [Google Scholar]
  19. Yasir M. Chauhan I. Zafar A. Verma M. Noorulla K.M. Tura A.J. Alruwaili N.K. Haji M.J. Puri D. Gobena W.G. Dalecha D.D. Sara U.V.S. Kumar N. Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: Formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation. J. Drug Deliv. Sci. Technol. 2021 61 102164 10.1016/j.jddst.2020.102164
    [Google Scholar]
  20. Mao S.R. Wang Y.Z. Ji H.Y. Bi D.Z. [Preparation of solid lipid nanoparticles by microemulsion technique] Yao Xue Xue Bao 2003 38 8 624 626 14628457
    [Google Scholar]
  21. Jojo G.M. Kuppusamy G. De A. Karri V.V.S.N.R. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer’s disease using Box-Behnken design. Drug Dev. Ind. Pharm. 2019 45 7 1061 1072 10.1080/03639045.2019.1593439 30922126
    [Google Scholar]
  22. Moghddam S.M.M. Ahad A. Aqil M. Imam S.S. Sultana Y. Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box–Behnken design approach. Artif. Cells Nanomed. Biotechnol. 2017 45 3 617 624 10.3109/21691401.2016.1167699 27050533
    [Google Scholar]
  23. Samanwita Khanra Parikshit Roychowdhury Gowthamarajan, Kuppusamy Development and validation of an rp uflc method for the estimation of oxaliplatin drug for the preparation of oxaliplatin nanoparticles. Curr. Pharm. Anal. 2024 20 8 863 873 10.2174/0115734129329774240829073320
    [Google Scholar]
  24. Weng J. Tong H.H.Y. Chow S.F. In vitro release study of the polymeric drug nanoparticles: Development and validation of a novel method. Pharmaceutics 2020 12 8 732 10.3390/pharmaceutics12080732 32759786
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096414252251125053406
Loading
Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer
Bentham Science Publishers ; https://doi.org/10.2174/0115680096414252251125053406
/content/journals/ccdt/10.2174/0115680096414252251125053406
/content/journals/ccdt/10.2174/0115680096414252251125053406
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: box-behnken design ; targeted drug delivery ; solid lipid nanoparticles ; anticancer activity ; Oxaliplatin ; colorectal cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test